���构特征与受体作用机制 — Explained

By Editorial Desk · published 2026-02-09 · last reviewed 2026-03-31 · Faq

A practical reference on freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-03-31 and is reviewed periodically as new material appears.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Semaglutide Background and Drug Class

Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.

Semaglutide at a glance

Handling, Storage, and Characterization

Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.

Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.

Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.

Related pages on this site

• Connected digest
• Proven update
• Regional toolkit
• Structured summary
• Structured archive
• Durable review
• Professional digest
• Comprehensive analysis

Background and Receptor Mechanism

The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.

Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.

Handling, Storage, and Analytical Verification

Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.

Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.

Molecular Background and Drug Class

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Reference notes

== Epidemiology == Prevalence of disease in a rigorous meta-analysis in 2017 was 46 patients per million. The earliest published prevalence was in 2000 and put at 5 per million. A 2017 study in Ireland reported 112 per million. It is not believed that the disease prevalence is increasing with time, but rather diagnostics and reporting are improving. Estimates of the mean age of onset range from 61 to 68 years old.

Nervous tissue is composed of neurons, also called nerve cells, and neuroglial cells. Four types of neuroglia found in the CNS are astrocytes, microglial cells, ependymal cells, and oligodendrocytes. Two types of neuroglia found in the PNS are satellite glial cells and Schwann cells. In the central nervous system (CNS), the tissue types found are grey matter and white matter. The tissue is categorized by its neuronal and neuroglial components.

=== Hypothalamic === While all neurons use glucose for fuel, certain glucose-sensing neurons alter their firing rates in response to rising or falling levels of glucose. These glucose-sensing neurons are concentrated primarily in the ventromedial nucleus and arcuate nucleus of the hypothalamus, which regulate many aspects of glucose homeostasis (especially the response to hypoglycemia), fuel utilization, satiety and appetite, and weight maintenance. These neurons are most sensitive to glucose changes in the 0.5–3.5 mM glucose range. Glucokinase has been found in the brain in largely the same areas that contain glucose-sensing neurons, including both of the hypothalamic nuclei. Inhibition of glucokinase abolishes the ventromedial nucleus response to a meal. However, brain glucose levels are lower than plasma levels, typically 0.5–3.5 mM. Although this range is matches the sensitivity of the glucose-sensing neurons, it is below the optimal inflection sensitivity for glucokinase. The presumption, based on indirect evidence and speculation, is that neuronal glucokinase is somehow exposed to plasma glucose levels even in the neurons.

=== Liberal Leaders in the House of Lords === Granville Leveson-Gower, 2nd Earl Granville (1859–1865) John Russell, 1st Earl Russell (1865–1868) Granville Leveson-Gower, 2nd Earl Granville (1868–1891) John Wodehouse, 1st Earl of Kimberley (1891–1894) Archibald Primrose, 5th Earl of Rosebery (1894–1896) John Wodehouse, 1st Earl of Kimberley (1896–1902) John Spencer, 5th Earl Spencer (1902–1905) George Robinson, 1st Marquess of Ripon (1905–1908) Robert Crewe-Milnes, 1st Marquess of Crewe (1908–1923) Edward Grey, 1st Viscount Grey of Fallodon (1923–1924) William Lygon, 7th Earl Beauchamp (1924–1931) Rufus Isaacs, 1st Marquess of Reading (1931–1936) Robert Crewe-Milnes, 1st Marquess of Crewe (1936–1944) Herbert Samuel, 1st Viscount Samuel (1944–1955) Philip Rea, 2nd Baron Rea (1955–1967) Frank Byers (1967–1984) Nancy Seear, Baroness Seear (1984–1989)

Metallothionein (MT) is a family of cysteine-rich, low molecular weight (MW ranging from 500 to 14000 Da) proteins. They are localized to the membrane of the Golgi apparatus. MTs have the capacity to bind both physiological (such as zinc, copper, selenium) and xenobiotic (such as cadmium, mercury, silver, arsenic, lead) heavy metals through the thiol group of its cysteine residues, which represent nearly 30% of its constituent amino acid residues. MT was discovered in 1957 by Vallee and Margoshe from purification of a cadmium-binding protein from horse (equine) renal cortex. MT plays a role in the protection against metal toxicity and oxidative stress, and is involved in zinc and copper regulation. There are four main isoforms expressed in humans (family 1, see chart below): MT1 (subtypes A, B, E, F, G, H, L, M, X), MT2, MT3, and MT4. In the human body, large quantities are synthesised primarily in the liver and kidneys. Their production is dependent on availability of the dietary minerals such as zinc, copper, and selenium, as well as the amino acids histidine and cysteine. Metallothioneins are rich in thiols, causing them to bind a number of trace metals. Metallothionein is one of the few eukaryotic proteins playing a substantial role in metal detoxification. Zinc and cadmium are tetrahedrally coordinated to cysteine residues, and each metallothionein protein molecule may bind up to 7 atoms of Zn or Cd. The biosynthesis of metallothionein appears to increase several-fold during periods of oxidative stress to shield the cells against cytotoxicity and DNA damage.

Sources: en.wikipedia.org

Reference notes

The official name of the country, according to the constitution adopted concurrently with the UDI in November 1965, was Rhodesia, which derives from Cecil Rhodes. This was not the case under British law, however, which considered the territory's legal name to be Southern Rhodesia, the name given to the country in 1898 during the British South Africa Company's administration of the Rhodesias, and retained by the self-governing colony of Southern Rhodesia after the end of company rule in 1923. This naming dispute dated back to October 1964, when Northern Rhodesia became independent from the UK and concurrently changed its name to Zambia. The Southern Rhodesian colonial government in Salisbury felt that in the absence of a "Northern" Rhodesia, the continued use of "Southern" was superfluous. It passed legislation to become simply Rhodesia, but the British government refused to approve this on the grounds that the country's name was defined by British legislation, so could not be altered by the colonial government. Salisbury went on using the shortened name in an official manner nevertheless, while the British government continued referring to the country as Southern Rhodesia. This situation continued throughout the UDI period.

Thyroid Stimulating Hormone (TSH) (University of Washington Medical Center). September 2011. Method: Access 2 (Beckman Coulter). Thyroid Stimulating Hormone (TSH) (Collaborative Laboratory Services). September 2011. Method: Access 2 (Beckman Coulter). Thyroid Stimulating Hormone (TSH). September 2009. Method: Access 2 (Beckman Coulter). Lab 18 Thyroid Stimulating Hormone. 2001-2002. Method: Microparticle Enzyme Immunoassay. Lab 18 TSH - Thyroid Stimulating Hormone. 1999-2000. Method: Microparticle Enzyme Immunoassay.

=== Documentaries === Hofmann's Potion Archived June 16, 2021, at the Wayback Machine a documentary on the origins of LSD, 2002 Inside LSD National Geographic Channel, 2009 How to Change Your Mind Archived June 16, 2022, at the Wayback Machine Netflix docuseries, 2022

== See also == Ambient ionization Atmospheric pressure chemical ionization Atmospheric pressure photoionization Desorption atmospheric pressure photoionization Desorption electrospray ionization Electric glow discharge

It is also used off-label in the management of moderate to severe cases of serotonin syndrome, a complex of symptoms associated with the use of serotonergic drugs, such as selective serotonin reuptake inhibitors (and monoamine oxidase inhibitors), and in cases of high levels of serotonin in the blood resulting from a serotonin-producing carcinoid tumor. There is uncertainty about the proper dose of cyproheptadine for treatment of serotonin syndrome, with doses of 4 to 16 mg having been employed but doses of 20 to 30 mg possibly actually being necessary based on positron emission tomography (PET) imaging research. Cyproheptadine has sedative effects and can be used to treat insomnia similarly to other centrally-acting antihistamines. The recommended dose for this use is 4 to 8 mg.

Sources: en.wikipedia.org

Notes from published material

26 October In two studies, scientists report findings about the role of epigenetics – which is shaped during lifetime – in colorectal cancer, including that it is a major component of how an individual tumor varies and findings about its influences on the accumulation of DNA mutations and cancer phenotypes. At the 30th anniversary of the World Scientists' Warning to Humanity, scientists conclude that "We are now at 'code red' on planet Earth", facing a climate emergency, warning citizens and world leaders to take necessary actions with information about tracked "recent climate-related disasters, assess[ed] planetary vital signs, and [...] policy recommendations". A study concludes that cosmic radiation events in the tree-ring radiocarbon record called "Miyake events", don't appear to be caused by the solar cycle (i.e. solar flares) as thought previously and have extended durations. They occurred every ~1,000 years on average and may threaten global technologies this century. A magnetical guidance system with engineered bacterial microbots (see also 22 September above) for 'precision targeting' is demonstrated to be effective for fighting cancer in mice. 31 October Multiple traces of monkeypox are detected in non-sewered wastewater with sparse sampling from a densely populated metropolitan area in Asia. A new record for the longest-frozen embryos to ever result in a live birth is reported in the United States, with twins born after storage for 30 years.

=== Ships === HMS C4, a C-class submarine of the British Royal Navy Spanish submarine C-4, a C-class submarine of the Spanish Navy Type C4 ship, merchant cargo ships of US Maritime Commission "C" design USS C-4 (SS-15), a C-class submarine of the US Navy USS Philadelphia (C-4), a protected cruiser of the US Navy

==== Computer tomography ==== In 1972, the first commercial CT scanner for clinical use went into operation at Atkinsons Morley Hospital in London. Its inventor was the English engineer Godfrey Newbold Hounsfield (1919-2004), who shared the 1979 Nobel Prize in Medicine with Allan McLeod Cormack (1924-1998) for his pioneering work in the field of computed tomography. The first steps toward dose reduction were taken in 1989 in the era of single-slice spiral CT. The introduction of multi-slice spiral computed tomography in 1998 and its continuous development made it possible to reduce the dose by means of dose modulation. The tube current is adjusted, for example by reducing the power for images of the lungs compared to the abdomen. The tube current is modulated during rotation. Because the human body has an approximately oval cross-section, radiation intensity is reduced when radiation is delivered from the front or back, and is increased when radiation is delivered from the side. This dose control also depends on the body mass index. For example, the use of dose modulation in the head and neck region reduces total exposure and organ doses to the thyroid and eye lens by up to 50% without significantly compromising diagnostic image quality. The Computed Tomography Dose Index (CTDI) is used to measure radiation exposure during a CT scan. The CTDI was first defined by the Food and Drug Administration (FDA) in 1981. The unit of measurement for the CTDI is the mGy (milli-Gray).

, as in "Notation"), which are non-linear polynomial functions of δD and δ13C values. Such non-linearity can be a diagnostic signature for mixing if multiple samples of various mixing ratios can be measured. When end-members have similar δ13C or δD compositions, the non-linearity is negligible.

Sources: en.wikipedia.org

Frequently asked questions